Results 271 to 280 of about 25,999 (347)

Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study [PDF]

, 2018
et al,, Gambacorti-Passerini, Carlo, Van Tine, Brian A   +2 more
core   +1 more source

Sex differences in neuromodulatory subcortical systems and their implications for Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 3, March 2026.
Abstract Neuromodulatory subcortical systems (NSSs) are uniquely susceptible to dementia‐related pathology, leading to frequent molecular and behavioral impairments associated with altered function of these nuclei. Some of these systems display clear sex‐specific cytoarchitecture and signaling leading to distinct physiology and behavioral outputs in ...
Rosaria J. Rae, Jessica Marie Hunter Alberhasky, Marion Baillet, Debra A. Bangasser, Michael E. Belloy, Anne S. Berry, Chiara Berteotti, Hannah Bow, Rachel Buckley, Jessica Z. K. Caldwell, Matteo Carpi, Benjamin J. Clark, Claire J. Ciampa, Alexander C. Conley, Martin J. Dahl, Zoe R. Donaldson, Alexander J. Ehrenberg, Gillian Einstein, Neus Falgàs, Haley A. Fenlon, Megan C. Fitzhugh, Robert C. Froemke, Clara Gallay, Lea Tenenholz Grinberg, Derek A. Hamilton, Zia Hasan, Oihane Uriarte Huarte, Shaista Jabeen, Heidi I. L. Jacobs, Louis John Kolling, Elouise A. Koops, Sabrina Lenzoni, Claudio Liguori, Riccardo Manca, Catherine A. Marcinkiewcz, Tamunotonye Omoluabi, Rademene Oria, Caitlin A. Orsini, Nancy Elizabeth Ortega, Judy Pa, Nathan S. Pentkowski, Joana B. Pereira, Rhudovic Ramos, Derya Sargin, Abhijit Satpati, Maria Clara Selles, Mabel Seto, Shabana M. Shaik, Shireen Sindi, Gowoon Son, Valentine Ucheagwu, Maxime Van Egroo, Qi Yuan, Michael A. Kelberman   +53 more
wiley   +1 more source

Specialist Neurology Involvement and Impact in Immune Checkpoint Inhibitor-Related Neurotoxicity: Experience in a Unified Healthcare System. [PDF]

Cancers (Basel)
Schroeder B, Prasad P, Gbadegesin O, Gupta S, Frazer R, Heaney S, Franks H, Blair C, Stuttard M, Barlow C, Cook H, Winter H, d'Arienzo P, Symington J, Radif Y, Rampes S, Nathan P, Young K, Shaw H, Carr A, Willis M.   +20 more
europepmc   +1 more source

[Hibernation in the neurotoxic syndrome in children].

Revista chilena de pediatria, 2000
F, MILIA, O, ALASIA, A, BOGERO
openaire   +1 more source

Anatomical Progression of Neuropathology in FTLD‐TDP Type C and Linkage to Annexin A11

Annals of Neurology, Volume 99, Issue 3, Page 639-655, March 2026.
Objective Frontotemporal lobar degenerations (FTLD)‐TDP type C (TDP‐C) is distinguished from other FTLD‐TDP subtypes by 3 unique features: (1) invariable onset in the anterior temporal lobe (ATL), (2) phosphorylated TDP‐43 (pTDP) neurites in cortex, and (3) colocalization of all pTDP deposits with annexin A11 (ANXA11).
Allegra Kawles, Caroline Nelson, Ivan Ayala, Elena Barbieri, Rudolph Castellani, Changiz Geula, Tamar Gefen, M. Marsel Mesulam   +7 more
wiley   +1 more source

A case of folinic acid, fluorouracil and oxaliplatin (FOLFOX) chemotherapy regimen associated neurotoxicity and review of literature. [PDF]

BMC Neurol
Srivastava J, DO EK, Sivakumar S, Mullaguri N.   +3 more
europepmc   +1 more source

Final Efficacy and Safety Results of Pyrotinib Combined With Trastuzumab and Chemotherapy in Pre‐Treated Human Epidermal Growth Factor Receptor 2‐Positive Metastatic Breast Cancer

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Purpose Findings from our previous study showed that the combination of pyrotinib, trastuzumab, and chemotherapy represents a viable treatment strategy with an acceptable safety profile for heavily pre‐treated human epidermal growth factor receptor 2 (HER2)‐positive metastatic breast cancer (MBC).
Xiaofeng Xie, Daijia Huang, Jiayi Huang, Xuelian Chen, Xue Bai, Wenyu Zheng, Liping Chen, Xiaofeng Lan, Lin Song, Rongmei Lei, Caiwen Du   +10 more
wiley   +1 more source

Case Report: Rare adverse events following CAR-T therapy in patients with relapsed/refractory diffuse large B-cell lymphoma. [PDF]

Front Oncol
Shah Z, Kunwor R.
europepmc   +1 more source

Impact of Thiazides and Fluoropyrimidines Interaction on Myelotoxicity and Other Adverse Events in Real‐World Practice: A Retrospective Cohort Study

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Introduction The European Summary of Product Characteristics (SmPC) for 5‐FU warns of significant granulocyte decline when combined with thiazides, cyclophosphamide, or methotrexate, based on a 1981 cohort of 14 patients. Despite limited evidence, drug‐interaction checkers still flag this risk.
Gerard Ronda‐Roca, José Porcel‐Maleno, Mónica Lobo‐Palomar, Gustavo Centeno‐Soto, Ana Ruiz‐Casado, Belén Ruiz‐Antorán   +5 more
wiley   +1 more source